Owens & Minor, Inc.

Owens & Minor, Inc. (OMI) Market Cap

Owens & Minor, Inc. has a market capitalization of $207.1M.

Price: $2.68

0.22 (8.94%)

Market Cap: 207.07M

NYSE · time unavailable

CEO: Edward A. Pesicka

Sector: Healthcare

Industry: Medical - Distribution

IPO Date: 1980-03-17

Website: https://www.owens-minor.com

Owens & Minor, Inc. (OMI) - Company Information

Market Cap: 207.07M|Sector: Healthcare

Company Profile

Owens & Minor, Inc., along with its affiliated entities, operates as a global provider of healthcare solutions, serving markets both within the United States and internationally. Its business is structured into two primary divisions: Global Solutions and Global Products. The Global Solutions segment delivers a comprehensive array of products and services tailored for healthcare providers and manufacturers. This includes a range of medical and surgical provisions, encompassing both well-known brands and O&M's own proprietary items. Additionally, this division offers crucial services to healthcare providers, such as supplier management, data analytics, inventory control, and clinical supply oversight. It also develops various programs to provide logistical support and marketing strategies for its network of suppliers. Conversely, the Global Products segment focuses on manufacturing and procuring medical and surgical items designed to prevent infections acquired in healthcare settings, serving both acute care facilities and alternative site channels. Its diverse product portfolio features sterilization wraps, surgical drapes and gowns, facial protection gear, various protective apparel, medical examination gloves, customized and minor procedure kits, among other essential medical supplies. O&M supplies its extensive range of offerings directly to a broad client base, which includes large multi-facility healthcare provider networks, independent hospitals, surgical centers, physician's practices, and hospital systems. Distribution also occurs indirectly through collaborations with third-party partners. Founded in 1882, the company maintains its principal corporate office in Richmond, Virginia.

Analyst Sentiment

47%
Hold

From 5 Active Polls

1Y Forecast: $15.60

▲ +482.1% Potential Upside

Consensus Target Metrics

Low Bound

$4

Median

$10

High Bound

$37

Average

$16

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$15.60
▲ +482.09% Upside
Low Target
$4.00
49% Risk
Median Target
$10.00
273% Mid
High Target
$37.00
1281% Max
Consensus
Hold
3 / 10 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)2071752153717006981,0091,210999
Enterprise Value ($M)2,0702,0092,1672,5352,7642,9103,0993,3373,128
Price to Earnings Ratio (P/E)-0.22-6.74-0.96-0.62-0.20-7.05-0.85-23.07-7.75
Price/Earnings-to-Growth Ratio (PEG)-0.06-0.27-0.00-5.76-2.19
Price to Sales Ratio (P/S)0.090.280.300.531.030.270.371.761.51
Price to Book Ratio (P/B)-0.51-0.38-0.47-0.86-2.491.221.781.381.16
Price to Free Cash Flow Ratio (P/FCF)-1.207.983.65-1.61-14.44-7.00123.50-35.3614.20
Enterprise Value to Sales (EV/Sales)3.203.063.644.051.111.154.864.74
Enterprise Value to EBITDA (EV/EBITDA)8.7825.8043.4828.32147.7448.47-15.5936.4639.11
Debt to Equity Ratio7.77-4.67-4.85-5.11-7.483.983.792.482.77

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 OWENS & MINOR INC (OMI) — Investment Overview

🧩 Business Model Overview

Owens & Minor (OMI) operates as an end-to-end healthcare supply chain provider to hospitals and other care settings. The value chain centers on sourcing and sourcing management (medical/surgical products and related services), fulfillment through a distribution and logistics network, and ongoing contract-based supply programs that optimize product availability and cost for provider customers.

In practice, OMI embeds into customer operations through structured purchasing arrangements, replenishment processes, and service-level agreements. This tends to create customer stickiness because the “switch” is not merely changing a vendor—it involves reconfiguring procurement workflows, item setup, logistics routing, systems integration, and operational service expectations.

💰 Revenue Streams & Monetisation Model

OMI monetizes primarily through:

  • Distribution and fulfillment revenue—largely tied to customer contract volumes and product throughput.
  • Contracted supply services—recurring elements driven by service-level agreements, program management, and logistics/operations support.
  • Value-added solutions—where applicable, incremental revenue streams can come from services layered onto distribution (e.g., inventory management and supply program execution).

Margin drivers typically include product mix, contract structure, warehouse and transportation efficiency, procurement scale, and the ability to manage working capital (inventory and receivables). Because a meaningful portion of revenues is tied to physical movement and service delivery, operating leverage is influenced by volume discipline, logistics productivity, and cost control rather than pure pricing power.

🧠 Competitive Advantages & Market Positioning

OMI’s core moat is best characterized as a combination of high switching costs and cost advantages from scale and execution rather than intangible brand-driven pricing.

  • Switching Costs (Contract + Systems + Operations): Provider contracts, SKU/item onboarding, integration with procurement and ordering workflows, service-level commitments, and logistics routing create friction for customers considering alternatives.
  • Cost Advantage (Distribution Network & Procurement Scale): Healthcare distribution is operationally intensive; competitors must match service reliability, warehouse/transport efficiency, and sourcing terms to compete on economics.
  • Intangible Barriers (Qualification + Operational Trust): Hospitals and health systems require vendor qualification, consistent compliance, and operational reliability, which can slow competitive displacement.

Competitive benchmarking:

  • McKesson: Broad healthcare distribution and services footprint; competes across similar hospital supply chain categories with larger scale.
  • Cardinal Health: Diversified healthcare supply and distribution model; competes on distribution efficiency and service programs.
  • AmerisourceBergen (now part of Cardinal Health’s broader market context through industry structure, but historically a key comparator): Competes in supply distribution to providers and related services.
  • Medline (additional comparator): Strong in healthcare distribution with differentiated service offerings.

OMI’s positioning tends to differentiate on service execution for specific provider needs and contract execution discipline within healthcare distribution—rather than competing on a single product category or proprietary technology. Against large peers, its competitiveness often hinges on operational reliability, customer integration depth, and the economics of contracted supply programs.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, growth is driven less by “headline” demand and more by structural procurement and care-delivery changes:

  • Outsourcing of supply chain functions: Providers continue to seek operational focus and supply chain expertise, supporting demand for contracted distribution and logistics.
  • Healthcare utilization remains structurally resilient: Aging demographics and chronic disease prevalence underpin product consumption, supporting ongoing distribution volumes.
  • Inventory optimization and service-level expectations: Better-managed supply programs (availability, reduced stockouts, controlled waste) support continued contract renewals and program expansions.
  • Consolidation among providers: Integrated delivery networks (IDNs) often centralize purchasing, which can expand TAM for national-capable supply partners; the key is maintaining service performance across system sites.
  • Shift toward value-based operating models: As providers target cost discipline, supply chain efficiency becomes a measurable lever, favoring vendors that can deliver consistent total cost of care through logistics and contracting.

⚠ Risk Factors to Monitor

  • Customer concentration and contract churn: Losing contracts or experiencing delayed renewals can pressure volumes and absorption of fixed costs.
  • Healthcare cost pressure and budget tightening: Demand can soften when hospitals reduce discretionary spending or slow elective procedure volumes.
  • Margin volatility from mix and logistics costs: Transportation, labor, and warehouse costs can fluctuate, while competitive contract pricing can compress gross margin.
  • Working capital and inventory risk: Distribution economics depend on disciplined inventory management; changes in demand forecasting can increase cash conversion stress.
  • Cyber and operational resilience: Systems integration and order execution create exposure to cyber incidents and operational disruptions.
  • Regulatory and compliance demands: Healthcare supply chains face ongoing compliance expectations; failures can result in loss of qualification or remediation costs.

📊 Valuation & Market View

Healthcare distribution is typically valued on cash flow and earnings quality rather than high-multiple growth narratives. In most market frameworks, valuation commonly emphasizes:

  • EV/EBITDA as a baseline for industrial/service-like distribution models.
  • Operating margin durability and free cash flow conversion, given sensitivity to working capital and logistics efficiency.
  • Quality of revenue—contracted and service-linked revenue tends to be viewed more favorably than purely transactional exposure.

Key drivers that move the market’s view typically include contract win/loss trajectory, margin consistency, cost-to-serve discipline, and cash conversion performance.

🔍 Investment Takeaway

OMI fits a value-and-cash-flow framework within healthcare supply chain services. The investment case rests on customer stickiness from switching costs (contracts, systems, and operational integration) and scale-driven cost advantages that support service-level delivery. Sustained execution in contract management, logistics productivity, and working-capital discipline can allow OMI to compound earnings power over a multi-year horizon, even as the industry remains competitive.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for OMI.

accessnewswire.com2026-07-13

Orosur Mining Inc Announces Holding(s) in Company

LONDON, UK / ACCESS Newswire / July 13, 2026 / Orosur Mining Inc. (TSX.V:OMI)(AIM:OMI)(OTC PINK:OROXF) TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : OROSUR MINING INC 1b.

proactiveinvestors.co.uk2026-06-09

Orosur Mining says new drilling has given fresh view of APTA gold prospect

Orosur Mining Inc (AIM:OMI, TSX-V:OMI) said fresh drilling at its APTA prospect in Colombia has reshaped its view of the target, with the first new hole returning a broad gold intersection and opening three areas for follow-up. Hole MAP-106A returned 229.7 metres at 0.88 grams per tonne gold, including several higher-grade intervals: 6.85 metres at 2.15 g/t, 59.2 metres at 2.02 g/t, 7.65 metres at 7.07 g/t and 4.7 metres at 3.95 g/t.

gurufocus.com2026-06-03

Honda and the Honda USA Foundation Support Hundreds of Programs Expanding Opportunity Across the U.S.

Honda and the Honda USA Foundation Support Hundreds of Programs Expanding Opportunity Across the U.S. PR Newswire

accessnewswire.com2026-06-01

Orosur Mining Inc Announces Total Voting Rights

LONDON, UK / ACCESS Newswire / June 1, 2026 / Orosur Mining Inc. ("Orosur" or "the Company") (AIM:OMI)(TSXV:OMI), a minerals explorer and developer with projects in Colombia and Argentina, advises that during May 2026, the Company issued 2,850,000 new common shares of no par value each ("Common Shares") following the exercise of 2,850,000 restricted stock units (as announced on 19 May 2026) and 2,206,000 Common Shares for a total consideration of Cdn$551,500 following the exercise of 2,206,000 warrants at a price of Cdn$0.25 from its block listing announced on 14 January 2026. For the purposes of the Disclosure Guidance and Transparency Rules, the Company has 401,005,074 Common Shares in issue.

accessnewswire.com2026-05-19

Orosur Mining Inc Announces Exercise of RSUs

LONDON, UK / ACCESS Newswire / May 19, 2026 / Orosur Mining Inc. ("Orosur" or the "Company") (TSXV:OMI)(AIM:OMI) announces that the Company has issued 2,850,000 Common Shares ("Shares") representing 0.72% of the Company's current issued share capital, following the exercise of 2,850,000 restricted stock units ("RSUs") by directors, officers, and consultants of the Company. All of the Directors will be retaining their Shares and not selling after exercise, other than Thomas Masney, one of the Company's Non-Executive Directors, who will sell 75,000 Shares to cover the tax due on the Shares issued to him.

accessnewswire.com2026-05-01

Orosur Mining Inc Announces Granting of RSUs

Granting of RSUs LONDON, UK / ACCESS Newswire / May 1, 2026 / Orosur Mining Inc. ("Orosur" or "the Company") (TSXV:OMI)(AIM:OMI) announces the granting of an aggregate of 13,650,000 Restricted Stock Units ("RSUs") to directors, officers, employees and consultants of the Company, upon recommendation of the Company's Remuneration Committee, in recognition of the Company's progress and as incentivisation for future performance. At the Company's AGM held on 17 December 2025, shareholders voted to permit the Company to maintain a "rolling" securities-based compensation plan, reserving for issuance, a maximum of 10% of the issued shares of the Company from time to time.

accessnewswire.com2026-04-30

Orosur Mining Inc. Announces Total Voting Rights

LONDON, UK / ACCESS Newswire / April 30, 2026 / Orosur Mining Inc. ("Orosur" or "the Company") (AIM:OMI)(TSXV:OMI), a minerals explorer and developer with projects in Colombia and Argentina, advises that for the purposes of the Disclosure Guidance and Transparency Rules, the Company has 395,949,074 Common Shares in issue. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

accessnewswire.com2026-04-29

Orosur Mining Inc Announces Results for the Third Quarter ended February 28

LONDON, UK / ACCESS Newswire / April 29, 2026 / Orosur Mining Inc. ("Orosur" or "the Company") (TSX-V:OMI)(AIM:OMI) the minerals explorer and developer with operations in Colombia and Argentina, announces its unaudited results for the quarter ended February 28th, 2026. All dollar figures are stated in US$ unless otherwise noted.

accessnewswire.com2026-04-28

Orosur Mining Inc Announces El Cedro Sampling Opens New Horizons

Soil sampling completed at El Cedro south - prospectivity enhanced Aeromag over El Cedro and APTA now completed Pepas rig moved from Pepas West to new target LONDON, UK / ACCESS Newswire / April 28, 2026 / Orosur Mining Inc. ("Orosur" or the "Company") (TSXV:OMI)(AIM:OMI), is pleased to announce an update on the progress of exploration activities at the Company's exploration project at Anzá in Colombia ("Anzá"). Anzá - Colombia The Anzá Project in Colombia comprises a number of granted exploration titles and applications totalling roughly 330km2, within the Mid-Cauca gold belt, west of the city of Medellin.

proactiveinvestors.co.uk2026-04-14

Orosur Mining shares rise 19% after new gold zone discovered near Pepas deposit in Colombia

Orosur Mining Inc (AIM:OMI, TSX-V:OMI) shares rose 19% to 21.1p after the company reported the discovery of a new gold mineralised zone 100 metres west of its Pepas deposit at the Anzá project in Colombia. Drill hole PEP082 intersected 26.4 metres at 2.85 grams per tonne gold from 5.3 metres depth, while the follow-up hole PEP083 returned 14.45 metres at 8.27 grams per tonne from surface, including a high-grade interval of 2.55 metres at 42.7 grams per tonne.

accessnewswire.com2026-03-26

Orosur Mining Inc. Announces 43-101 Technical Report for its Anza Project

Orosur files 43-101 technical report for its Anza Project in Colombia LONDON, UK / ACCESS Newswire / March 26, 2026 / Orosur Mining Inc. (" Orosur " or the " Company ") (TSXV:OMI)(AIM:OMI) , is pleased to announce the filing of a National Instrument 43-101 - Standards of Disclosure for Mineral Projects - compliant technical report in support of the Company's 100%-owned Anza Project in Colombia including its maiden Mineral Resource Estimate for the Pepas deposit. Effective date of the report is 16 th January 2026, and issue date is 25 th March 2026.

accessnewswire.com2026-02-27

Orosur Mining Inc Announces Total Voting Rights

LONDON, UK / ACCESS Newswire / February 27, 2026 / Orosur Mining Inc. ("Orosur" or "the Company") (AIM:OMI)(TSXV:OMI), a minerals explorer and developer with projects in Colombia and Argentina, advises that during February 2026, the Company has issued 1,316,949 new common shares of no par value each ("Common Shares") for a total consideration of US$110,703 following the exercise of 1,016,949 warrants at a price of US$0.0558 and 300,000 warrants at a price of Cdn$0.25 respectively from its block listing announced January 14, 2026. For the purposes of the Disclosure Guidance and Transparency Rules, the Company has 394,547,125 Common Shares in issue.

defenseworld.net2026-01-31

Owens & Minor (NYSE:OMI) versus RBC Life Sciences (OTCMKTS:RBCL) Head to Head Survey

Owens and Minor (NYSE: OMI - Get Free Report) and RBC Life Sciences (OTCMKTS:RBCL - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings. Profitability This table compares Owens and

accessnewswire.com2026-01-30

Orosur Mining Inc Announces Total Voting Rights

LONDON, UNITED KINGDOM / ACCESS Newswire / January 30, 2026 / Orosur Mining Inc. ("Orosur" or "the Company") (TSXV:OMI)(AIM:OMI) , a minerals explorer and developer with projects in Colombia and Argentina, advises that during January 2026, the Company has issued 1,857,949 new common shares of no par value each ("Common Shares") for a total consideration of US$286,160 following the exercise of 1,471,000 warrants at a price of Cdn$0.25 and 386,949 warrants at a price of US$0.0558 respectively from its block listing announced January 14, 2026. For the purposes of the Disclosure Guidance and Transparency Rules, the Company has 394,547,125 Common Shares in issue.

proactiveinvestors.co.uk2026-01-26

Orosur Mining shares up on exploration update

Orosur Mining Inc (AIM:OMI, TSX-V:OMI) shares gained 8% after an update which outlined exploration activity, which highlighted that infill drilling continued at its Pepas gold prospect in Anzá as it works toward a NI 43-101 compliant mineral resource estimate. Orosur said: “As anticipated, drilling results have firmed up the Pepas deposit and provided a better definition of the nature of the thick, high-grade mineralisation.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"OMI reported Q1 2026 revenue of $627.8M and a net loss of $23.6M (net margin: -3.8%). EPS was not available in the provided dataset (eps = 0). On a QoQ basis, revenue fell sharply from Q4 2025 (-$1.249B to $627.8M), while net loss improved from Q4 2025 (net loss narrowed from -$56.3M to -$23.6M). On a YoY comparison versus Q1 2025, revenue declined materially ($2.632B to $627.8M; ~-76.1%), and losses remained, though slightly improved (net loss of -$23.6M vs -$25.0M; ~+5.8% improvement). Profitability is still weak and volatile: net margin moved from about -0.9% in Q1 2025 to -1.0% in Q3 2025 and then a sharp change in Q4 2025 (dataset inconsistencies in ratios), before ending at -3.8% in Q1 2026. Operating income was positive in Q1 2026 ($17.1M) despite a negative bottom line, indicating non-operating items (net other income/expense) are weighing on pretax and net income. Cash flow shows improved operating profitability at the period level (net cash from operations not populated, but the company generated $54.9M net cash for the quarter, with $72.0M investing outflows likely for capex). The balance sheet remains financially stressed: total equity is negative (-$464.8M), with high leverage (total debt $648.7M) but substantial cash ($336.9M). No dividends or buybacks were reported; total shareholder return cannot be assessed from the provided marketPerformance fields (price and 1y_change are undefined). Revenue and Earnings-based metrics were included here because the company is not indicated as pre-revenue; however, the dataset shows inconsistencies across quarters that may affect ratio reliability."

Revenue Growth

Neutral

QoQ revenue decreased sharply (Q4 2025: -$1.249B to Q1 2026: $627.8M, dataset anomaly) and YoY revenue declined ~-76.1% ($2.632B to $627.8M), indicating significant contraction.

Profitability

Neutral

Net income remained negative in Q1 2026 (-$23.6M) but improved YoY vs Q1 2025 (-$25.0M). Margins were still negative (net margin -3.8%); operating income was positive ($17.1M) showing partial improvement despite non-operating drag.

Cash Flow Quality

Neutral

Net loss persists, and operating cash flow is not reliably populated (0 in Q1 2026). Cash increased to $336.9M and the quarter ended with net cash increase of $54.9M, but equity is negative and no shareholder distributions/buybacks were shown.

Leverage & Balance Sheet

Caution

Equity is negative (-$464.8M) with total assets $2.42B and total debt $648.7M. Liquidity is moderate (cash $336.9M), but negative equity reduces resilience.

Shareholder Returns

Neutral

Dividend yield is 0 and no buybacks were reported. Total return from price momentum is not measurable because price and 1y_change are undefined in the provided marketPerformance data.

Analyst Sentiment & Valuation

Caution

Analyst targets are wide (low $4, high $37, consensus $15.6). Without a valid current price (marketPerformance.price = 0), upside/downside cannot be quantified, but sentiment appears mixed given the range.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

OMI/Accendra’s Q1 2026 results were roughly in-line operationally but masked by the large commercial payor exit. Reported revenue fell 6.8% YoY; excluding the payor impact, growth was ~1%. Adjusted EBITDA was $58M, with pressures from weaker collections, inflation, and higher health benefit expenses, offset by cost savings. Management is leaning on a transformation narrative: margins are described as moving from ~19% gross and ~4% EBITDA to nearly ~50% gross and double-digit EBITDA post-separation. The key financial lever is a balance sheet optimization resetting maturities and de-leveraging up to ~$115M, adding roughly $40M annualized interest (about half in 2H’26). Liquidity remains comfortable ($337M cash; $195M revolver capacity). The outlook is affirmed for 2026 (no numbers given), with at least 65% of adjusted EBITDA expected in Q3–Q4. In Q&A, analysts focused on free cash flow after financing and the rollout economics of sleep and diabetes channel strategies.

AI IconGrowth Catalysts

  • Sleep Journey driving strong YoY growth in sleep supplies; higher revenue per order, lower attrition, and improved therapy adherence via dedicated sleep coaches
  • Sleep Center of Excellence pilot succeeded in select markets; nationwide launch planned in Q2 to improve patient capture and adherence for PAP initiation
  • Category momentum led by ostomy and urology; large sleeve grew over 4% and home respiratory ~4% (excluding large commercial payor change)
  • Diabetes mixed: insulin pumps growth partially offset CGM drop; diabetes slightly down overall

Business Development

  • Exclusive multiyear extension with largest commercial payor for soft goods (ostomy, urology, diabetes, incontinence, among others)
  • Large commercial payor exit: sold substantial Accendra-owned patient service equipment for cash; transferred dedicated equipment, personnel, and certain variable/fixed costs to another industry player
  • Optum preferred provider agreements: ramp expected through 2026 (no named start date or additional partner details provided)

AI IconFinancial Highlights

  • Revenue declined 6.8% in Q1; excluding the large commercial payor impact, revenue growth would have been about 1%
  • Q1 adjusted EBITDA of $58 million was in line with expectations
  • Large commercial payor exit: equipment sold for $82 million cash; $52 million book gain; onetime income not included in adjusted EBITDA
  • Collection rate deterioration, inflationary product costs, and higher health benefit expenses pressured results; partially offset by cost savings and lower SG&A from adjusted execution/cost takeouts
  • Cash flow: free cash flow slightly negative in Q1 (seasonality + working capital sequencing)
  • Extraordinary cash payments: $19 million to the IRS for international transfer pricing matters (2015–2018) and $22 million of previously accrued P&HS divestiture expenses
  • Liquidity/debt snapshot: $337 million cash on balance sheet; $195 million available revolver capacity; net debt essentially flat at $1.77 billion vs. end of 2025

AI IconCapital Funding

  • Balance sheet optimization: received creditor commitments for a holistic reset; subject to customary closing conditions
  • Debt actions/targets: expected de-leveraging of up to ~$115 million; pay off 2027 maturities; retire Term Loan A due in 2027
  • Revolver: new $300 million committed revolving facility due in 2030; multiyear extension of revolver facility
  • Notes: exchange offers extending 2029/2030 notes into new secured notes maturing in 2032 (first lien) and 2033 (second lien)
  • Timing: completion expected in coming weeks; exchange offer closing targeted for mid-to-late June (third week, mid-to-late third week)
  • Interest impact: annualized cash interest estimated to be higher by about $40 million; approximately half expected to hit in 2H 2026
  • Capital allocation posture: management stated all incremental operating cash/free cash flow generation will be used for debt reduction

AI IconStrategy & Ops

  • Transition/separation from Owens & Minor on track; company expected to be fully independent per schedule
  • Exit substantially completed for previously disclosed large commercial payor; remaining smaller capitated agreements characterized as very small with “positive yield”
  • Cost structure transformation: repositioning into a leaner, nimbler, higher-margin model via centralization, standardization, and automation
  • Reported margin transformation: gross margin from ~19% range and EBITDA margins ~4% to nearly ~50% gross margins and double-digit EBITDA margins (post-divestiture context referenced)
  • SG&A: 1Q better than expected due to benefits from cost-saving; costs related to the large customer were removed in a two-phase process ending late Feb and late Mar

AI IconMarket Outlook

  • Company affirmed 2026 outlook for revenue and adjusted EBITDA (no numeric guidance disclosed in transcript)
  • Seasonality: at least 65% of adjusted EBITDA expected in Q3 and Q4
  • Financing exchange closing timing: launch actual exchange offer next week; close targeted for the third week, mid-to-late third week of June

AI IconRisks & Headwinds

  • Lower year-over-year collection rate continued as a headwind
  • Inflationary product cost increases and higher health benefit expenses
  • Home respiratory underperformed expectations “for the last few quarters”
  • Diabetes category volatility: CGM growth underperformed (insulin pumps growth did not fully offset CGM decline)
  • Optum onboarding/pref provider ramp takes time and may continue to require modeling adjustments throughout 2026

Q&A: Analyst Interest

  • Free cash flow and debt-reduction priority: Management said operating/free cash flow generated after financing and scheduled payments should all be used for debt reduction, but exact 2026 cash flow forecast depends on final financing terms and transaction timing, expected to become clearer after closing next month.
  • Diabetes channel mix (DME vs pharmacy) positioning: Management attributed stabilization opportunities to observed adherence differences between DME and pharmacy channels, noting stronger adherence with DME. They emphasized educating patients and providers on DME benefits, leveraging follow-up both with patients and providers to improve outcomes.
  • Sleep Journey + Sleep Center of Excellence rollout metrics: Management quantified progress qualitatively: Sleep Journey shows adherence improvement of single-digit percentage points each quarter and higher average order basket. Sleep Center of Excellence started in three markets, with full network implementation by early Q4, improving referral-to-therapy speed.

Sentiment: MIXED

Note: This summary was synthesized by AI from the OMI Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for OMI.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (OMI)

© 2026 Stock Market Info — Owens & Minor, Inc. (OMI) Financial Profile